SurgiMab

Executive Summary

SurgiMab is a Paris-based clinical-stage biotechnology company pioneering real-time fluorescence imaging solutions for cancer detection during surgery. Founded in 2016, the company's technology aims to enhance surgical precision by enabling surgeons to visualize tumor margins in real time, potentially reducing recurrence rates and improving patient outcomes. SurgiMab's platform targets multiple solid tumor types and is currently in Phase 1 clinical development. As a private company with no disclosed funding or valuation, it operates with limited public visibility but holds promise in the growing field of image-guided surgery. The company's progress through early-stage trials will be critical to validating its technology and attracting strategic partnerships or financing.

Upcoming Catalysts (preview)

• 2026Phase 1 data readout60% success
• 2027Initiation of Phase 2 trial40% success
• TBDPartnership or licensing deal30% success